2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
59
Carcinoma, Hepatocellular
46
Colorectal Neoplasms
33
Stomach Neoplasms
31
Esophageal Squamous Cell Carcinoma
27
Squamous Cell Carcinoma of Head and Neck
20
Esophageal Neoplasms
14
Small Cell Lung Carcinoma
13
Neoplasm Metastasis
13
Lung Neoplasms
13
Rectal Neoplasms
12
Head and Neck Neoplasms
12
Advanced Solid Tumor
12
Triple Negative Breast Neoplasms
11
Cholangiocarcinoma
11
Nasopharyngeal Carcinoma
10
Melanoma
10
Uterine Cervical Neoplasms
9
Recurrence
9
Neoplasms
9
Colonic Neoplasms
9
Pancreatic Neoplasms
7
Urinary Bladder Neoplasms
6
Solid Tumor
6
Carcinoma, Transitional Cell
6
Breast Neoplasms
6
Sarcoma
5
Lymphoma, Extranodal NK-T-Cell
5
Lymphoma
5
Hodgkin Disease
5
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Sunitinib
3
Specimen Handling
3
Paclitaxel
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Drug Therapy
3
Carboplatin
3
Biopsy
3
Abiraterone Acetate
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Suspensions
2
Surveys and Questionnaires
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
tislelizumab
×
Clear all
NCT04922047
2021-06-11
TACBIN-01
RenJi Hospital
Phase 1/2
Unknown
6 enrolled